Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review.

ABSTRACT:

Background and objective

Anaplastic lymphoma kinase (ALK) rearrangements are detected in 3-7% of advanced non-small cell lung cancer (NSCLC). There are currently 5 U.S Food and Drug Administration (FDA)-approved ALK tyrosine kinase inhibitors (TKIs) for the treatment of patients with ALK-positive lung cancer in the advanced/metastatic disease setting. Despite these advances, most patients with ALK-positive lung cancer who are treated with ALK TKI therapy ultimately experience disease progression due to various mechanisms of drug resistance. In this review, we discuss strategies to address acquired therapeutic resistance to ALK inhibition, novel agents and combinatorial strategies in development for both on and off-target resistance, and some emerging approaches to prolong response

SUBMITTER: Desai A 

PROVIDER: S-EPMC10087990 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature